Menu
1 min read · estimated
APPROVED USE
What FDA approved
Adults with low- to intermediate-1-risk myelodysplastic syndromes and transfusion-dependent anemia requiring at least four red-cell units in eight weeks, after inadequate or lost ESA response or when an ESA is unsuitable.
LAMPGEN ANALYSIS
Why it matters
The telomerase inhibitor offers an option centered on reducing transfusion dependence in a defined lower-risk MDS group.
What research teams should watch
Reconcile transfusions across hospitals to confirm the qualifying eight-week window and track cytopenias and transfusion-free intervals.
PRIMARY RECORDS